ArticleNeurologia medico-chirurgica2025
Impact of Clazosentan Use on Symptomatic Vasospasm and Early Ambulation in Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Cohort Study.
Article in Neurologia medico-chirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective cohort study investigated the association between the use of clazosentan and the incidence of symptomatic vasospasm, as well as rehabilitation-related outcomes, particularly, the timing of ambulation, in patients with aneurysmal subarachnoid hemorrhage. A total of 153 patients who underwent surgical clipping or endovascular coiling at our institution between January 2020 and March 2025 were included; among them, 76 received clazosentan, and 77 received conventional treatment.The primary outcomes were the incidence of symptomatic vasospasm and the number of days to initial ambulation. Secondary outcomes included changes in body weight, peripheral oxygen saturation, and laboratory parameters one week after drug administration.The incidence of symptomatic vasospasm was significantly lower in the clazosentan group (5.3%) than in the conventional treatment group (20.7%) (p = 0.007). In addition, ambulation was achieved significantly earlier in the clazosentan group (median: 8.5 days; interquartile range: 5-12) than in the control group (median: 11 days, interquartile range: 8-15) (p = 0.015).Conversely, one week after administration, the clazosentan group showed a significant increase in body weight and significant decreases in peripheral oxygen saturation, serum albumin, hemoglobin, and hematocrit levels, suggesting potential systemic effects.These findings suggest that clazosentan use may be associated with a lower incidence of symptomatic vasospasm and earlier ambulation in patients with aneurysmal subarachnoid hemorrhage; however, careful monitoring of systemic status is warranted during rehabilitation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.